Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Stomach Neoplasms 6Uterine Cervical Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1GastroEsophageal Cancer 1Gastric or Gastroesophageal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × bemarituzumab × Clear all
NCT06967987 2026-01-21

BEMAFLOT

Institut Cancerologie de l'Ouest

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

University of Chicago

Phase 2 Completed
80 enrolled 14 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡